U.S. markets closed

Acer Therapeutics Inc. (ACER)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1918+0.0218 (+1.86%)
At close: 12:59PM EST
1.1925 +0.00 (+0.06%)
After hours: 03:27PM EST

Acer Therapeutics Inc.

One Gateway Center
Suite 351 300 Washington Street
Newton, MA 02458
United States
844 902 6100

Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher SchellingFounder, Pres, CEO & Director436kN/A1976
Mr. Harry S. PalminChief Financial Officer382.4kN/A1970
Mr. Jefferson E. DavisChief Bus. Officer326.67kN/A1967
Ms. Tanya HaydenChief Operating OfficerN/AN/AN/A
Mr. John Michael KloppChief Technical OfficerN/AN/A1975
Mr. Donald R. Joseph J.D.Chief Legal Officer & Sec.N/AN/A1954
Mr. Bernie PaulChief People OfficerN/AN/A1959
Mr. Matthew T. SeibtChief Commercial OfficerN/AN/A1971
Dr. Adrian Quartel FFPM, M.D.Chief Medical OfficerN/AN/A1967
Mr. Jason Kneeland CPAVP of Fin. & ControllerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Corporate Governance

Acer Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.